全文获取类型
收费全文 | 3113篇 |
免费 | 313篇 |
国内免费 | 58篇 |
专业分类
耳鼻咽喉 | 36篇 |
儿科学 | 108篇 |
妇产科学 | 43篇 |
基础医学 | 389篇 |
口腔科学 | 61篇 |
临床医学 | 437篇 |
内科学 | 689篇 |
皮肤病学 | 196篇 |
神经病学 | 417篇 |
特种医学 | 137篇 |
外国民族医学 | 1篇 |
外科学 | 354篇 |
综合类 | 186篇 |
预防医学 | 181篇 |
眼科学 | 31篇 |
药学 | 165篇 |
2篇 | |
中国医学 | 21篇 |
肿瘤学 | 30篇 |
出版年
2024年 | 3篇 |
2023年 | 105篇 |
2022年 | 91篇 |
2021年 | 213篇 |
2020年 | 200篇 |
2019年 | 156篇 |
2018年 | 187篇 |
2017年 | 204篇 |
2016年 | 135篇 |
2015年 | 112篇 |
2014年 | 230篇 |
2013年 | 322篇 |
2012年 | 144篇 |
2011年 | 138篇 |
2010年 | 130篇 |
2009年 | 127篇 |
2008年 | 138篇 |
2007年 | 127篇 |
2006年 | 114篇 |
2005年 | 102篇 |
2004年 | 97篇 |
2003年 | 60篇 |
2002年 | 52篇 |
2001年 | 39篇 |
2000年 | 35篇 |
1999年 | 23篇 |
1998年 | 28篇 |
1997年 | 28篇 |
1996年 | 27篇 |
1995年 | 19篇 |
1994年 | 20篇 |
1993年 | 12篇 |
1992年 | 9篇 |
1991年 | 13篇 |
1990年 | 7篇 |
1989年 | 3篇 |
1988年 | 5篇 |
1987年 | 3篇 |
1986年 | 4篇 |
1985年 | 5篇 |
1984年 | 6篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1981年 | 2篇 |
1980年 | 1篇 |
1978年 | 2篇 |
1977年 | 1篇 |
1974年 | 2篇 |
1973年 | 1篇 |
排序方式: 共有3484条查询结果,搜索用时 15 毫秒
1.
目的 分析轻型/重型新型冠状病毒肺炎(COVID-19)患者的临床特征,探讨心肌型脂肪酸结合蛋白(H-FABP)与COVID-19轻重症的相关性。方法 回顾性分析2022年6月前重庆大学附属三峡医院收治的超敏肌钙蛋白T(hs-cTnT)表达阴性的COVID-19患者40例,根据《新型冠状病毒肺炎诊疗方案(试行第八版)》诊断标准,将患者分为轻型和重型两组,比较两组外周血中H-FABP表达水平差异。结果 符合纳入标准的COVID-19患者共40例,其中轻型组20例,重型组20例,与轻型组相比,重型组年龄更大[(41.9±10.5) vs (58.2±16.3)岁],且合并糖尿病比例更高(P均<0.05)。通过比较两组血清H-FABP表达水平发现,重型组H-FABP水平明显高于轻型组[(3.97±1.80) vs (6.88±3.90) μg/L,P<0.05]。结论 在hs-cTnT表达阴性的COVID-19患者中,血清H-FABP表达水平与COVID-19疾病严重程度相关,H-FABP可能作为一个更加敏感且独立的心肌损伤因子用于COVID-19疾病分型。 相似文献
2.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):445-450
PurposeTo evaluate the effectiveness and safety of fluoroscopy-guided percutaneous high ligation (FPHL) combined with fluoroscopy-guided foam sclerotherapy (FGFS) to treat varicose veins of the great saphenous veins (GSVs).Materials and MethodsThis was a retrospective study of 113 patients (mean age, 62.1 ± 10.8 years; 60 men) with varicose veins of the GSVs (133 limbs) that were treated with FPHL combined with FGFS between April 1 and October 31, 2019. Demographic and clinical data were collected from these patients before the FPHL procedure, after which FGFS was performed. The preterminal GSV was ligated percutaneously by a percutaneously-positioned polypropylene ligature under fluoroscopic guidance. The outcome of ligation was confirmed by venography. Then, foam sclerotherapy was performed under fluoroscopy. At 1-year follow-up, GSV occlusion was evaluated by ultrasound. The venous clinical severity scores (VCSSs) were compared between the preoperative and 1-year follow-up periods.ResultsThe technical success rate was 100% (133 limbs). Complete 12-month follow-up was available for 112 limbs (84.2%) and 103 of these limbs (92.0%) remained occluded during this period. The VCSS improved from 4.71 ± 2.15 to 0.74 ± 0.60 (V = 6328, P < .001). During follow-up, there were 16 limbs with thrombophlebitis and 38 limbs with saphenous junction pain; these events were alleviated within 2 weeks of the procedure. There was no deep venous thrombosis or other severe adverse events.ConclusionsFPHL combined with FGFS to treat varicose veins in the GSVs achieved an occlusion rate of 92% and improved the clinical symptoms within 1 year; this minimally-invasive procedure was safe and effective. 相似文献
3.
目的探究老年2型糖尿病(T2DM)并阻塞性睡眠呼吸暂停综合征(OSAS)患者25羟基维生素D[25(OH)D]和血小板参数[平均血小板体积(MPV)和血小板分布宽度(PDW)]变化及与OSAS严重程度的相关性。方法选择2016年10月—2021年10月于宁德师范学院附属宁德市医院诊治的61例老年T2DM合并OSAS患者为观察组,50例单纯T2DM患者为对照组。观察并比较2组基线资料及血25(OH)D、MPV、PDW水平,以及OSAS严重程度不同的患者25(OH)D、MPV和PDW水平,采用Logistic回归模型分析OSAS的影响因素。结果 2组BMI、高血压史、冠心病史、糖化血红蛋白(HbA1c)、高密度脂蛋白胆固醇(HDL-C)和尿酸(UA)差异具有统计学意义(P<0.05);观察组MPV和PDW显著高于对照组(P<0.05),25(OH)D低于对照组(P<0.05);OSAS严重程度不同的患者间25 (OH)D和血小板参数差异具有统计学意义(P<0.05),其中25(OH)D随着OSAS严重程度的增高而降低(P<0.05),MPV、PDW随着OSAS严重程度的增高而上升(P<0.05);Logistic回归分析结果显示,冠心病史、HbA1c、25(OH)D、MPV和PDW是OSAS发生的影响因素(P<0.05)。结论老年T2DM合并OSAS患者MPV和PDW变化呈现上升趋势,25(OH)D呈下降趋势,其水平变化与T2DM合并OSAS发生和病情关系密切。 相似文献
4.
5.
6.
《Research in social & administrative pharmacy》2022,18(8):3323-3328
BackgroundThe consistency in reporting the severity of drug interactions across the drug information resources is important in guiding the appropriate clinical use of drug-pairs, to minimize the associated adverse events. This necessitates the need of a standardized severity rating scale, that can accommodate the different severity ratings of the same interacting drug-pair into a reasonable severity category, that can ease the consistency assessment among different drug information resources.ObjectiveTo develop and validate a standardized severity rating scale that can ease the consistency assessment among the various drug information resources.MethodsThe definitions of various severity rating categories as documented in the eight drug information resources was consolidated to develop a standardized severity rating scale. Thus developed rating scale was validated using twenty commonly used drug-pairs. Fleiss' kappa score was used as an indicator for assessing overall consistency among various drug information resources, whereas, Cohen's kappa was used as an indicator of level of consistency between two drug information resources and between individual drug information resource and newly developed standardized severity rating scale.ResultsThe newly developed standardized severity rating scale classifies the severity of drug-drug interactions into three categories namely mild, moderate and major. The Fleiss' kappa score was improved from 0.047 to 0.176, indicating improved strength of agreement [Average pairwise agreement: 16% Vs 36.7%] among various drug information resources. The average pairwise Cohen's kappa was 0.082 [Strength of agreement: poor] in original severity ratings whereas it was improved to 0.198 [Strength of agreement: almost equal to fair] in standardized severity rating scale.ConclusionThe newly developed standardized severity rating scale can be used as a tool to assess the consistency of severity rating categories among the various drug information resources. 相似文献
7.
Wattana Leowattana Tawithep Leowattana Pathomthep Leowattana 《World Journal of Clinical Cases》2022,10(34):12470-12483
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has triggered a widespread outbreak since December 2019. The SARS-CoV-2 infection-related illness has been dubbed the coronavirus disease 2019 (COVID-19) by the World Health Organization. Asymptomatic and subclinical infections, a severe hyper-inflammatory state, and mortality are all examples of clinical signs. After attaching to the angiotensin converting enzyme 2 (ACE2) receptor, the SARS-CoV-2 virus can enter cells through membrane fusion and endocytosis. In addition to enabling viruses to cling to target cells, the connection between the spike protein (S-protein) of SARS-CoV-2 and ACE2 may potentially impair the functionality of ACE2. Blood pressure is controlled by ACE2, which catalyzes the hydrolysis of the active vasoconstrictor octapeptide angiotensin (Ang) II to the heptapeptide Ang-(1-7) and free L-Phe. Additionally, Ang I can be broken down by ACE2 into Ang-(1-9) and metabolized into Ang-(1-7). Numerous studies have demonstrated that circulating ACE2 (cACE2) and Ang-(1-7) have the ability to restore myocardial damage in a variety of cardiovascular diseases and have anti-inflammatory, antioxidant, anti-apoptotic, and anti-cardiomyocyte fibrosis actions. There have been some suggestions for raising ACE2 expression in COVID-19 patients, which might be used as a target for the creation of novel treatment therapies. With regard to this, SARS-CoV-2 is neutralized by soluble recombinant human ACE2 (hrsACE2), which binds the viral S-protein and reduces damage to a variety of organs, including the heart, kidneys, and lungs, by lowering Ang II concentrations and enhancing conversion to Ang-(1-7). This review aims to investigate how the presence of SARS-CoV-2 and cACE2 are related. Additionally, there will be discussion of a number of potential therapeutic approaches to tip the ACE/ACE-2 balance in favor of the ACE-2/Ang-(1-7) axis. 相似文献
8.
9.
10.